Table 2 |
|||||
|
Prospective Nested Case Control Studies of Selenium and Prostate Cancer. |
|||||
| Reference |
Study |
# Cases |
# Controls |
Outcomes |
Comment |
|
|
|||||
| [189] |
Physicians Health Study |
586 |
577 |
↑Se = ↓risk of advance prostate cancer (OR = 0.52, 95% CI = 0.28–0.98) |
Result only in men with PSA ≥ 4 ng/mL |
| [190] |
Netherlands Cohort Study |
540 |
1,211 |
↑Se = ↓risk prostate cancer (OR for quintiles of Se = 1.0, 1.05, 0.69, 0.75, 0.69; 95% CI = 0.48–0.99) |
Results greatest in ex-smokers |
| [191] |
Baltimore Longitudinal Study of Aging |
52 |
96 |
↑Se = ↓risk prostate cancer (OR for quartiles of Se = 1.0, 0.15, 0.21, 0.24 |
|
| [192] |
Washington County, Maryland |
117 |
233 |
Top 4/5 of Se had reduction in prostate cancer risk; statistically significant result for Se only when γtocopherol levels were high |
Men in top quintile of serum γtocopherol had 5-fold reduced risk of prostate cancer compared to lowest quintile |
| [193] |
Health Professional Follow-up Study |
181 |
181 |
↑Se = ↓risk of advanced prostate cancer |
Adjusted OR = 0.35 (95% CI = 0.16–0.78) |
| [194] |
Prospective study |
↑Se = ↓risk of gastrointestinal and prostate cancer |
Results not statistically significant |
||
Donaldson Nutrition Journal 2004 3:19 doi:10.1186/1475-2891-3-19 |
|||||
